ABC | Volume 111, Nº1, Julho 2018

Artigo Original Erturk et al. Adropina e Irisina Arq Bras Cardiol. 2018; 111(1):39-47 Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 13. OkoshiMP,RomeiroFG,PaivaSA,OkoshiK.Heartfailure-inducedcachexia. Arq Bras Cardiol. 2013;100(5):476-82. 14. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol. 2012;19(4):585-667. 15. Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Manuel Gómez J, et al. Bioelectrical impedance analysis: utilization in clinical practice. Clin Nutr. 2004;23(6):1430-53. 16. Pardo M, Crujeiras AB, Amil M, Aquera Z, Jimenez-Murcia S, Botella C, et al. Assocation of irisin with fat mass, resting energy expenditure, and daily activity in conditions of extreme body mass index. Int J Endocrinol. 2014;2014:857270. Doi 10.1155/2014/857270. Epub 2014 Apr 22. 17. InvernizziM,CardaS,CisariC;Società Italianaper loStudiodellaSarcopenia e della Disabilità Muscolo-Scheletrica (SISDIM). Possible synergism of physical exercise and ghrelin-agonists in patients with cachexia associated with chronic heart failure. Aging Clin Exp Res. 2014;26(4):341-51. 18. Doehner W, Frenneaux M, Anker SD. Metabolic impairment in heart failure: the myocardial and systemic perspective. J Am Coll Cardiol. 2014;64(13):1388-400. 19. Szabó T, Scherbakov N, Sandek A, Kung T, von Haehling S, Lainscak M, et al. Plasma adiponectin in heart failure with andwithout cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis. Nutr Metab Cardiovasc Dis. 2014;24(1):50-6. 20. Von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009;121(3):227-52. 21. Sente T, Van Berendocks AM, Hoymans VY, Vrints CJ. Adiponectin resistance in skelatal muscle: pathophysiological implications in chronic heart failure. J Cachexia Sarcopenia Muscle. 2016;7(3):261-74. 22. AshrafianH,FrenneauxMP,OpieLH.Metabolicmechanisms inheart failure. Circulation. 2007;116(4):434-48. 23. Butler AA, TamCS, Stanhope KL, Wolfe BM, Ali MR, O’KeeffeM, et al. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic diseaseand increase after gastric bypass surgery in humans. J Clin Endocrinol Metab 2012;97(10):3783-91. 24. LovrenF,PanY,QuanA,SinghKK,ShuklaPC,GuptaM,etal.Adropinisanovel regulatorofendothelial function.Circulation.2010;122(11Suppl):S185-92. 25. Zhang C, Zhao L, Xu W, Li J, Wang B, Gu X, et al. [Correlation of serum adropin level with coronary artery disease]. Zhonghua Yi Xue Za Zhi. 2014;94(16):1255-7. 26. Zhao LP, Xu WT, Wang L, You T, Chan SP, Zhao X, et al. Serum adropin level in patients with stable coronary artery disease. Heart Lung Circ. 2015;24(10):975-9. 27. Yu HY, Zhao P, Wu MC, Liu J, Yin W. Serum adropin levels are decreased in patients with acute myocardial infarction. Regul Pept. 2014;190- 191:46-9. 28. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium- dependent vasodilation is attenuated in patients with heart failure. Circulation. 1991;84(4):1589-96. 29. Novelle MG, Contreras C, Romero-Picó A, López M, Diéguez C. Irisin, two years later. Int J Endocrinol. 2013;2013:746281. 30. Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol. 2002;85(1):51-66. 31. Aydin S, Aydin S, Kobat MA, Kalayci M, ErenMN, YilmazM, et al. Decreased saliva/serum irisin concentrations in the acute myocardial infarction promising for being a new candidate biomarker for diagnosis of this pathology. Peptides. 2014 Jun; 56:141-5. 32. ShenS,GaoR,BeiY,LiJ,ZhangH,ZhouY,etal.SerumIrisinPredictsMortality RiskinAcuteHeartFailurePatients.CellPhysiolBiochem.2017;42(2):615-22. 47